• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

产大肠杆菌素的pks⁺大肠杆菌与结直肠癌发生关联的Meta分析

A Meta-Analysis on the Association of Colibactin-Producing pks+ Escherichia coli with the Development of Colorectal Cancer.

作者信息

Gaab Marcianne Elaine, Lozano Prim Olivette, Ibañez Danica, Manese Korina Diane, Riego Fatima May, Tiongco Raphael Enrique, Albano Pia Marie

机构信息

Department of Biological Sciences, College of Science, University of Santo Tomas, Manila, Philippines.

Department of Medical Technology, College of Allied Medical Professions, Angeles University Foundation, Angeles City, Philippines.

出版信息

Lab Med. 2023 Jan 5;54(1):75-82. doi: 10.1093/labmed/lmac072.

DOI:10.1093/labmed/lmac072
PMID:35960765
Abstract

OBJECTIVE

Previous studies on the association between pks+Escherichia coli and colorectal cancer (CRC) demonstrated conflicting results. Hence, we performed a meta-analysis to obtain more precise estimates.

METHODS

Related literature was obtained from PubMed, ScienceDirect, Google Scholar, and Cochrane Library. Data were then extracted, summarized, and subjected to analysis using Review Manager 5.4 by computing for the pooled odds ratios at the 95% confidence interval.

RESULTS

Overall analysis showed that individuals carrying pks+E coli had a greater risk of developing CRC. Subgroup analysis further showed that individuals from Western countries carrying pks+E coli and individuals with pks+E coli in their tissue samples had increased risk of developing CRC.

CONCLUSION

Results of this meta-analysis suggest that individuals with pks+E coli have a greater risk of developing CRC. However, more studies are needed to confirm our claims.

摘要

目的

先前关于携带聚酮合酶基因的大肠杆菌(pks⁺大肠杆菌)与结直肠癌(CRC)之间关联的研究结果相互矛盾。因此,我们进行了一项荟萃分析以获得更精确的估计值。

方法

从PubMed、ScienceDirect、谷歌学术和Cochrane图书馆获取相关文献。然后提取数据、进行总结,并使用Review Manager 5.4通过计算95%置信区间的合并比值比进行分析。

结果

总体分析表明,携带pks⁺大肠杆菌的个体患结直肠癌的风险更高。亚组分析进一步表明,来自西方国家且携带pks⁺大肠杆菌的个体以及组织样本中含有pks⁺大肠杆菌的个体患结直肠癌的风险增加。

结论

这项荟萃分析的结果表明,携带pks⁺大肠杆菌的个体患结直肠癌的风险更高。然而,需要更多研究来证实我们的观点。

相似文献

1
A Meta-Analysis on the Association of Colibactin-Producing pks+ Escherichia coli with the Development of Colorectal Cancer.产大肠杆菌素的pks⁺大肠杆菌与结直肠癌发生关联的Meta分析
Lab Med. 2023 Jan 5;54(1):75-82. doi: 10.1093/labmed/lmac072.
2
Prevalence and implications of pKs-positive Escherichia coli in colorectal cancer.结直肠癌中 pKs 阳性大肠埃希菌的流行情况及其意义。
Life Sci. 2024 Mar 15;341:122462. doi: 10.1016/j.lfs.2024.122462. Epub 2024 Jan 27.
3
Pks-positive Escherichia coli in tumor tissue and surrounding normal mucosal tissue of colorectal cancer patients.结直肠癌患者肿瘤组织及周围正常黏膜组织中 Pks 阳性大肠埃希菌。
Cancer Sci. 2024 Apr;115(4):1184-1195. doi: 10.1111/cas.16088. Epub 2024 Jan 31.
4
Putrescine Supplementation Limits the Expansion of pks+ Escherichia coli and Tumor Development in the Colon.腐胺补充限制了 pks+ 大肠杆菌在结肠中的扩张和肿瘤发展。
Cancer Res Commun. 2024 Jul 1;4(7):1777-1792. doi: 10.1158/2767-9764.CRC-23-0355.
5
pks Escherichia coli more prevalent in benign than malignant colorectal tumors.pks 大肠杆菌在良性结直肠肿瘤中比恶性肿瘤更为普遍。
Mol Biol Rep. 2021 Jul;48(7):5451-5458. doi: 10.1007/s11033-021-06552-1. Epub 2021 Jul 23.
6
Association of Escherichia coli containing polyketide synthase in the gut microbiota with colorectal neoplasia in Japan.肠道微生物群中含聚酮合酶的大肠杆菌与日本结直肠癌的关系。
Cancer Sci. 2022 Jan;113(1):277-286. doi: 10.1111/cas.15196. Epub 2021 Nov 22.
7
Klebsiella pneumoniae producing bacterial toxin colibactin as a risk of colorectal cancer development - A systematic review.产细菌毒素 colibactin 的肺炎克雷伯菌作为结直肠癌发展的风险因素——一项系统综述。
Toxicon. 2021 Jul 15;197:126-135. doi: 10.1016/j.toxicon.2021.04.007. Epub 2021 Apr 24.
8
The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment.细菌遗传毒素 colibactin 通过改变肿瘤微环境促进结肠肿瘤生长。
Gut Microbes. 2014;5(5):675-80. doi: 10.4161/19490976.2014.969989.
9
Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer.肠毒素型大肠杆菌诱导的突变在类器官和结直肠癌中的检测得到改善。
Cancer Cell. 2024 Mar 11;42(3):487-496.e6. doi: 10.1016/j.ccell.2024.02.009.
10
Colibactin possessing E. coli isolates in association with colorectal cancer and their genetic diversity among Pakistani population.与结直肠癌相关的具有 colibactin 的大肠杆菌分离株及其在巴基斯坦人群中的遗传多样性。
PLoS One. 2022 Nov 11;17(11):e0262662. doi: 10.1371/journal.pone.0262662. eCollection 2022.

引用本文的文献

1
Association between Helicobacter pylori and Hepatobiliary Cancer: A Meta-analysis and Systematic Review.幽门螺杆菌与肝胆管癌的关系:荟萃分析和系统评价。
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3363-3370. doi: 10.31557/APJCP.2024.25.10.3363.
2
Towards Understanding Tumour Colonisation by Probiotic Bacterium Nissle 1917.深入了解益生菌Nissle 1917对肿瘤的定殖作用
Cancers (Basel). 2024 Aug 26;16(17):2971. doi: 10.3390/cancers16172971.
3
Early-onset cancers: Biological bases and clinical implications.早发性癌症:生物学基础及临床意义。
Cell Rep Med. 2024 Sep 17;5(9):101737. doi: 10.1016/j.xcrm.2024.101737. Epub 2024 Sep 10.
4
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.结直肠癌细胞中 colibactin 的耐药性与同源重组效率和伊立替康耐药性相关。
Cell Rep Med. 2024 Feb 20;5(2):101376. doi: 10.1016/j.xcrm.2023.101376. Epub 2024 Jan 15.
5
Association between physical activity and the prevalence of tumorigenic bacteria in the gut microbiota of Japanese adults: a cross-sectional study.体力活动与日本成年人肠道微生物群中致瘤菌流行率的关联:一项横断面研究。
Sci Rep. 2023 Nov 27;13(1):20841. doi: 10.1038/s41598-023-47442-9.
6
Three specific gut bacteria in the occurrence and development of colorectal cancer: a concerted effort.三种特定的肠道细菌在结直肠癌的发生和发展中:协同作用。
PeerJ. 2023 Aug 4;11:e15777. doi: 10.7717/peerj.15777. eCollection 2023.
7
Microbiome and Diet in Colon Cancer Development and Treatment.肠道微生物组与饮食在结直肠癌发生发展及治疗中的作用
Cancer J. 2023;29(2):89-97. doi: 10.1097/PPO.0000000000000649.